Last reviewed · How we verify
AI-09
At a glance
| Generic name | AI-09 |
|---|---|
| Sponsor | Eirion Therapeutics Inc. |
| Modality | Biologic |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- A Study to Evaluate AI-09 In Participants With Glabellar Lines (PHASE2)
- AI-09 In Subjects With Glabellar Lines, GL-101 (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- AI-09 CI brief — competitive landscape report
- AI-09 updates RSS · CI watch RSS
- Eirion Therapeutics Inc. portfolio CI